Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Yasmin Post Marketing Surveillance

This study has been completed.
Information provided by (Responsible Party):
Bayer Identifier:
First received: June 17, 2009
Last updated: November 10, 2015
Last verified: November 2015
The objective of this Post Marketing Surveillance (PMS) is to gain information about safety and efficacy in real practice.

Condition Intervention
Drug: EE30/DRSP (Yasmin, BAY86-5131)

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Yasmin Regulatory Post Marketing Surveillance

Further study details as provided by Bayer:

Primary Outcome Measures:
  • Safety and efficacy in real practice [ Time Frame: After 6 cycle of treatment ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Demography [ Time Frame: At initial visit ] [ Designated as safety issue: No ]
  • Medical History [ Time Frame: At initial visit ] [ Designated as safety issue: No ]
  • Administration period of Yasmin [ Time Frame: After 6 cycle of treatment or at the point of withdrawan ] [ Designated as safety issue: No ]
  • Patient's compliance [ Time Frame: After 6 cycle of treatment or at the point of withdrawan ] [ Designated as safety issue: No ]
  • Adverse Event / Serious AE collection [ Time Frame: At point of the occurence ] [ Designated as safety issue: Yes ]

Enrollment: 777
Study Start Date: December 2007
Study Completion Date: August 2013
Primary Completion Date: May 2013 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1 Drug: EE30/DRSP (Yasmin, BAY86-5131)
Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Korean women who need oral contraceptive

Inclusion Criteria:

  • Women who need oral contraceptive

Exclusion Criteria:

  • Patient who belongs to contraindication listed on the product label.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00923572

Korea, Republic of
Many Locations, Korea, Republic of
Sponsors and Collaborators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer Identifier: NCT00923572     History of Changes
Other Study ID Numbers: 14339  YA0510KR 
Study First Received: June 17, 2009
Last Updated: November 10, 2015
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Bayer:
Oral contraceptive

Additional relevant MeSH terms:
Drospirenone and ethinyl estradiol combination
Reproductive Control Agents
Physiological Effects of Drugs processed this record on December 02, 2016